Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

ClinicalTrials.gov ID: NCT00159653

Public ClinicalTrials.gov record NCT00159653. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.

Study identification

NCT ID
NCT00159653
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
500 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2005
Primary completion
May 31, 2007
Completion
May 31, 2007
Last update posted
Feb 20, 2021

2005 – 2007

United States locations

U.S. sites
38
U.S. states
20
U.S. cities
33
Facility City State ZIP Site status
Pfizer Investigational Site Phoenix Arizona 85032
Pfizer Investigational Site Poway California 92064
Pfizer Investigational Site Redding California 96002-2122
Pfizer Investigational Site Redding California 96002
Pfizer Investigational Site Danbury Connecticut 06810-4004
Pfizer Investigational Site Cape Coral Florida 33904
Pfizer Investigational Site Lakeland Florida 33805-2440
Pfizer Investigational Site Ormond Beach Florida 32174
Pfizer Investigational Site Tampa Florida 33603
Pfizer Investigational Site Atlanta Georgia 30322
Pfizer Investigational Site Atlanta Georgia 30342
Pfizer Investigational Site Atlanta Georgia 30349
Pfizer Investigational Site Morrow Georgia 30260
Pfizer Investigational Site Homewood Illinois 60430
Pfizer Investigational Site Overland Park Kansas 66213
Pfizer Investigational Site Louisville Kentucky 40207
Pfizer Investigational Site Shreveport Louisiana 71104
Pfizer Investigational Site North Dartmouth Massachusetts 02747
Pfizer Investigational Site Saint Joseph Michigan 49085
Pfizer Investigational Site Lincoln Nebraska 68506
Pfizer Investigational Site Omaha Nebraska 68198-5540
Pfizer Investigational Site Newark New Jersey 07103-2499
Pfizer Investigational Site Bethpage New York 11714-5701
Pfizer Investigational Site New York New York 10029-6574
Pfizer Investigational Site Charlotte North Carolina 28210
Pfizer Investigational Site Charlotte North Carolina 28262
Pfizer Investigational Site High Point North Carolina 27262
Pfizer Investigational Site Matthews North Carolina 28105
Pfizer Investigational Site Wilmington North Carolina 28403
Pfizer Investigational Site Tulsa Oklahoma 74104
Pfizer Investigational Site Cranberry Township Pennsylvania 16066
Pfizer Investigational Site Pittsburgh Pennsylvania 15238-3103
Pfizer Investigational Site Mt. Pleasant South Carolina 29464-3060
Pfizer Investigational Site Mt. Pleasant South Carolina 29464
Pfizer Investigational Site North Charleston South Carolina 29406
Pfizer Investigational Site Memphis Tennessee 38119
Pfizer Investigational Site Amarillo Texas 79106
Pfizer Investigational Site Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00159653, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 20, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00159653 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →